S.A.N.E Vax calls on US Senator Grassley to expand NCI ethics investigation

In a letter addressed to US Senator Charles Grassley, the vaccine safety non-profit organization S.A.N.E Vax congratulated the senator on his recent efforts to examine ethical questions raised by National Cancer Institute (NCI) employees accepting extensive travel sponsored by private companies and identified two senior NCI scientists who knowingly promote unreliable human papillomavirus (HPV) tests for patient care, and the development/monitoring of genotype-specific HPV vaccines to promote an unproven virology-based cervical cancer prevention business agenda.

One of the two NCI senior scientists recently admitted that he works with the US Food and Drug Administration and the NCI in the human papillomavirus (HPV) vaccine trial project, as well as working on the development of HPV tests, which were previously marketed by Digene Corp and are now by Qiagen, the Dutch company which acquired the US firm in 2007.

These two senior NCI scientists have co-authored, with the chief scientific officer of Digene, a total of 36 articles endorsing the only FDA-approved Digene HC2 HPV test in the USA. The NCI endorsements undoubtedly boosted the final sales price of Digene to Qiagen at $1.6 billion, said Norma Erickson, S.A.N.E Vax’ president.